Jiangsu Hengrui Medicine
600276.SS
#531
Rank
A$62.98 B
Marketcap
$9.87
Share price
0.02%
Change (1 day)
17.88%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): A$1.23 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are A$3.63 Billion. In 2023 the company made an earning of A$1.05 Billion, an increase over its 2022 earnings that were of A$0.94 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) A$1.23 B16.79%
2023 A$1.05 B11.4%
2022 A$0.94 B-13.65%
2021 A$1.09 B-34.21%
2020 A$1.67 B15.95%
2019 A$1.44 B33.03%
2018 A$1.08 B20.89%
2017 A$0.89 B23.89%
2016 A$0.72 B11.21%
2015 A$0.65 B39.5%
2014 A$0.46 B20.61%
2013 A$0.38 B11.46%
2012 A$0.34 B29.7%
2011 A$0.26 B31.16%
2010 A$0.20 B27.92%
2009 A$0.15 B5.8%
2008 A$0.15 B79.95%
2007 A$83.74 M32.89%
2006 A$63.02 M38.19%
2005 A$45.6 M21.56%
2004 A$37.51 M13.95%
2003 A$32.92 M38.06%
2002 A$23.84 M